About Oxford Nanopore Technologies
Oxford Nanopore Technologies is a biotechnology company that develops and commercializes nanopore sequencing technology.
Headquarters
Oxford Nanopore Technologies, Oxford
Founded
2005-01-01
Industry
Biopharma, Biotechnology, Genetics, Health Diagnostics, Nanotechnology
Last Funding Type
Post Ipo Equity
Valuation
2
Total Funding
$1.56 billion dollars
IPO Status
Public
Financial
Oxford Nanopore Technologies reported widening losses, delaying its break-even point. The company has also entered into strategic collaborations, including a partnership with SeqOne for rare disease DNA diagnostics and another with Plasmidsaurus to advance plasmid sequencing. Additionally, Oxford Nanopore Technologies has made a strategic shift targeting growth.
Oxford Nanopore Technologies has launched a new Pharmacogenomics (PGx) Beta Program to advance personalized medicine. Additionally, the company announced a strategic collaboration with Plasmidsaurus to enhance plasmid sequencing. Barclays has adjusted its price target for Oxford Nanopore Technologies' shares, reducing it to GBP1.60 from GBP1.85 while maintaining an overweight rating.
Oxford Nanopore Technologies has launched a new Pharmacogenomics (PGx) Beta Program to advance personalized medicine. Additionally, the company announced a strategic collaboration with Plasmidsaurus to enhance plasmid sequencing. Barclays has adjusted its price target for Oxford Nanopore Technologies' shares, reducing it to GBP1.60 from GBP1.85 while maintaining an overweight rating.
Funding Rounds
20
Number of Lead Investors
9
Total Funding Amount
$1.56 billion dollars
Number of Investors
23